<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2019.91003</article-id><article-id pub-id-type="publisher-id">WJCR-28367</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20190100000_76033376.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  DKK4增强结肠癌细胞5-FU耐药的作用和意义
  Effect of DKK4 Enhancing 5-FU Resistance in Colon Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>志良</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曾</surname><given-names>祥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>厚巍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>佳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>海鹰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>广州医科大学附属肿瘤医院胃肠肿瘤外科，广东 广州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>24</day><month>12</month><year>2018</year></pub-date><volume>09</volume><issue>01</issue><fpage>13</fpage><lpage>20</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：观察DKK4在结肠癌肝转移组织中的表达差异和DKK4基因对结肠癌细胞耐受5-FU的作用。方法：收集17例同时性结肠癌肝转移肿瘤组织，通过免疫组化分析原发灶和转移灶DKK4蛋白的表达差异。利用CRISPR-Cas9技术敲除人结肠癌SW480细胞DKK4基因，使用蛋白电泳和RT-PCR评估基因编辑效果，并分析DKK4表达对结肠癌细胞耐受5-FU杀伤的影响。结果：在17例结肠癌肝转移组织中，原发灶DKK4染色阳性率为20% (2/10)，肝转移灶染色阳性率70% (7/10)，提示肝转移灶DKK4蛋白表达明显高于结肠原发灶。利用CRISPR/Cas9技术成功敲除人结肠癌SW480细胞DKK4基因，在含有5%、10% 5-FU的培养基中，WT-DKK4 SW480细胞可继续增殖，但DKK4-KO SW480细胞则随5-FU浓度增加而加速死亡。结论：结肠癌肝转移灶组织中DKK4表达更高，且DKK4表达水平对结肠癌细胞耐受5-FU杀伤有极为重要的影响，提示DKK4可能是影响肿瘤耐受5-FU化疗的重要因素和潜在治疗靶点。
    Aims: To investigate the expression difference of DKK4 protein between primary colon cancer and liver metastases, and fluorouracil-tolerated effect of DKK4 gene in human colon cancer cells. Methods: Synchronous colon cancer liver metastasis cases and tissue samples were collected, ex-pression of DKK4 between colon cancer and liver metastasis were analyzed via immunohistochem-istry (IHC). DKK4 gene in human SW480 colon cancer cells was knocked out via CRISPR/Cas9 tech-nique and gene editing efficiency was analyzed by Western Blotting and Real-time PCR. Also, 5-FU resistance was tested for investigating the importance of DKK4 in colon cancer. Results: In 17 colon cancer liver metastasis cases, positive rate of DKK4 expressions were 35% in primary site and 75% in liver metastasis, which showed that liver metastases had higher DKK4 expression than colon primary sites. We successfully knocked out DKK4 gene in human SW480 colon cancer cells by using CRISPR/Cas9. Wild-type SW480 cells grew normally in 5%/10% 5-FU culture medium, while DKK4-KO SW480 cells accelerated death with increasing 5-fu concentration. Conclusion: DKK4 ex-pression was higher in liver metastasis than in colon primary site, and was critical to 5-FU tolerance in colon cancer. This result indicated that DKK4 was an important factor in 5-FU resistance and a potential therapeutics target. 
  
 
</p></abstract><kwd-group><kwd>DKK4蛋白，结肠癌肝转移，化疗耐药，基因编辑, Dickkopf-4</kwd><kwd> Colon Cancer Liver Metastasis</kwd><kwd> Chemotherapy Resistance</kwd><kwd> Gene-Editing</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>DKK4增强结肠癌细胞5-FU耐药的作用和意义<sup> </sup></title><p>黄志良，曾祥，徐厚巍，王佳，刘海鹰</p><p>广州医科大学附属肿瘤医院胃肠肿瘤外科，广东 广州</p><p><img src="//html.hanspub.org/file/3-2150164x1_hanspub.png" /></p><p>收稿日期：2018年12月11日；录用日期：2019年1月1日；发布日期：2019年1月8日</p><disp-formula id="hanspub.28367-formula17"><graphic xlink:href="//html.hanspub.org/file/3-2150164x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：观察DKK4在结肠癌肝转移组织中的表达差异和DKK4基因对结肠癌细胞耐受5-FU的作用。方法：收集17例同时性结肠癌肝转移肿瘤组织，通过免疫组化分析原发灶和转移灶DKK4蛋白的表达差异。利用CRISPR-Cas9技术敲除人结肠癌SW480细胞DKK4基因，使用蛋白电泳和RT-PCR评估基因编辑效果，并分析DKK4表达对结肠癌细胞耐受5-FU杀伤的影响。结果：在17例结肠癌肝转移组织中，原发灶DKK4染色阳性率为20% (2/10)，肝转移灶染色阳性率70% (7/10)，提示肝转移灶DKK4蛋白表达明显高于结肠原发灶。利用CRISPR/Cas9技术成功敲除人结肠癌SW480细胞DKK4基因，在含有5%、10% 5-FU的培养基中，WT-DKK4 SW480细胞可继续增殖，但DKK4-KO SW480细胞则随5-FU浓度增加而加速死亡。结论：结肠癌肝转移灶组织中DKK4表达更高，且DKK4表达水平对结肠癌细胞耐受5-FU杀伤有极为重要的影响，提示DKK4可能是影响肿瘤耐受5-FU化疗的重要因素和潜在治疗靶点。</p><p>关键词 :DKK4蛋白，结肠癌肝转移，化疗耐药，基因编辑</p><disp-formula id="hanspub.28367-formula18"><graphic xlink:href="//html.hanspub.org/file/3-2150164x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-2150164x7_hanspub.png" /> <img src="//html.hanspub.org/file/3-2150164x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 研究背景</title><p>结直肠癌是全球肿瘤相关死亡率第二最高的恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.28367-ref1">1</xref>] ，其发病率和死亡率近年在我国有持续升高的趋势。尽管5-氟尿嘧啶类(5-FU)药物为基础的化疗方案能有效提高结直肠癌的无瘤生存率和晚期肿瘤的缓解率，但结直肠癌患者存在不同程度的5-Fu耐药 [<xref ref-type="bibr" rid="hanspub.28367-ref2">2</xref>] ；且这种耐药性尚无有效地预测，一旦肿瘤对氟尿嘧啶类药物形成耐药，临床上难以逆转。因此，寻找一种能有效预测、减少或对抗肿瘤细胞5-FU耐药性形成的分子靶点，是提高结直肠癌临床疗效和降低死亡率的重要手段。</p><p>目前研究发现，人类DKK4 (dickkopf homolog 4)蛋白的表达水平与氟尿嘧啶类化疗耐药性有密切关系 [<xref ref-type="bibr" rid="hanspub.28367-ref3">3</xref>] ：结肠癌组织中DKK4表达增多的患者多表现出对5-FU化疗耐药；转染DKK4-cDNA的结肠癌细胞可明显增强对5-FU的耐受性，并有较高的存活率。我们的前期研究也发现：肝转移瘤中DKK4 mRNA的表达水平明显高于结肠原发病灶(74倍)，两者组织DKK4 mRNA表达差异与其5-FU化疗敏感性差异相一致 [<xref ref-type="bibr" rid="hanspub.28367-ref4">4</xref>] 。因此，本文章拟首先通过临床肿瘤标本检测对比原发肿瘤与肝转移瘤中DKK4蛋白的表达差异，再通过CRISPR-Cas9技术敲除人结肠癌细胞DKK4的表达，进行体外细胞培养和5-FU试验，初步分析DKK4表达对结肠癌细胞耐受5-FU的影响。</p></sec><sec id="s4"><title>2. 研究方法</title><sec id="s4_1"><title>2.1. 实验材料</title><p>人结肠癌细胞株SW480由我院肿瘤研究所实验室传代和保存。细胞培养使用RPMI-1640细胞培养液(含10%新生小牛血清、青霉素100 U/ml、链霉素100 U/ml)，在37℃、5%CO<sub>2</sub>培养箱中进行传代培养。转染后的SW480细胞使用相同培养方法和条件。</p></sec><sec id="s4_2"><title>2.2. DKK4基因CRISPR/Cas9编辑敲除</title><sec id="s4_2_1"><title>2.2.1. DKK4-gRNA的设计</title><p>利用人类DKK4 DNA序列在软件上设计可行的gRNA序列(https://wwws.blueheronbio.com/external/tools/gRNASrc.jsp)；根据所提供的可行gRNA序列选择3段合适的序列由OriGene技术公司进行gRNA质粒构建和包装。候选片段序列：1) 5’ ATGGTGGCGGCCGTCCTGCT 3’；2) 5’ TCCTGGACTTCAACAACATC 3’ (图1)。分别使用2条候选gRNA构建质粒进行后续体外细胞敲除实验，以确定效率最高的gRNA片段。</p><p>图1. CRISPR/Cas9工作原理</p></sec><sec id="s4_2_2"><title>2.2.2. CRISPR/Cas9质粒转染和验证</title><p>转染前18~24小时将待转染的SW480细胞以3 &#215; 10<sup>5</sup>个/孔接种于6孔板，待细胞扩增至5 &#215; 10<sup>5</sup>个/孔。转染前15分钟先将gRNA和模板DNA等量混合于Opti-MEM，然后缓慢加入待转染细胞培养液中；转染24小时后更换新鲜培养液，并使用1.5 ug/ml puromycin (Gibco, A11138-03)进行药物筛选；72小时后将细胞以1:10传代扩增，继续使用1.5 ug/ml puromycin对阳性细胞进行筛选，并观察细胞荧光表达情况(有GFP荧光者代表转染成功)。经药物初步筛选后的DKK4 knock-out SW480人结肠癌细胞进行GFP荧光流式细胞分选。分选后的GFP阳性细胞继续培养72小时，待检测验证。</p></sec><sec id="s4_2_3"><title>2.2.3. 细胞DKK4 knock-out效果验证</title><p>对经药物筛选和流式分选的阳性细胞进行DKK4蛋白水平(Western blot)和核酸水平(RT-PCR)检测：收集经转染的SW480结肠癌细胞，提取总蛋白。40 ug蛋白行12% SDS-聚丙烯酰胺凝胶电泳(SDS-PAGE)，电泳转膜，室温封闭2 h，抗人DKK4一抗(Abcam, ab38589) (Origene, TA302466) 4℃孵育过夜，二抗室温反应2 h，DAB法显色结果，经凝胶成像系统处理分析，计算灰度值；以&#223;-actin为内参对照。</p><p>RT-PCR检测：按RNeasy试剂盒(QIAGEN)说明书操作步骤提取细胞DNA，提取后测OD260、OD260/OD280评估DNA含量与纯度。使用PCR反应体系(Origene公司)进行DKK4 RT-PCR基因表达分析。反应条件如下：预变性94℃ &#215; 6 min；变性94℃ &#215; 1 min、退火54℃ &#215; 30 s、延伸72℃ &#215; 1 min，40个循环；4℃恒温保存。PCR结果由BIO-RAD系统进行阅读和分析。</p></sec></sec><sec id="s4_3"><title>2.4. 体外细胞5-FU药敏实验和生长曲线绘制</title><p>将筛选阳性的SW480细胞以5 &#215; 10<sup>3</sup>个/孔接种于培养板上进行培养，24小时后更换培养液并分别加入10 ug/ml、50 ug/ml的5-FU进行处理。每48小时更换一次新鲜培养液并行活细胞计数。记录每孔活细胞数变化并绘制曲线。</p></sec><sec id="s4_4"><title>2.5. 免疫组化染色</title><p>收集2017年临床中进行同期手术切除的结肠癌肝转移病例，术前未接受抗肿瘤治疗。结肠原发灶和肝转移灶组织均经HE染色证实腺癌。免疫组化染色采用二步法进行：组织切片脱蜡、水化、修复抗原，PBS洗涤后加入3%过氧化氢阻断内源性过氧化物酶，反应10分钟，稀释一抗孵育4℃过夜，PBS洗涤3次后二抗孵育室温30分钟，二氨基联苯氨(DAB)染色。DKK4阳性染色评分根据既往文献方法进行 [<xref ref-type="bibr" rid="hanspub.28367-ref5">5</xref>] ：DKK4蛋白在肿瘤组织中定位于胞浆，按细胞着色程度评分为：棕褐色3分，棕黄色2分，淡黄色1分，无着色为0分。按着色细胞的数量评分：一个视野内着色细胞大于75%为4分，51%~75%为3分，11%~50%为2分，小于10%为1分，阴性为0分。最后两者相加，0~3分为阴性表达，4~6分为阳性表达。结果判断由2名病理科医师双盲阅片。</p></sec><sec id="s4_5"><title>2.6. 统计分析</title><p>连续变量以均数 &#177; 标准差形式表示，用t检验进行比对分析；免疫组化实验结果采用半定量等级分析，用非参数检验进行比对。采用SPSS 13.0统计软件进行统计学分析。以P &lt; 0.05为具有显著性差异。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. DKK4在结肠癌原发灶和肝转移灶的表达差异</title><p>从临床数据库中收集到17例同期进行结肠癌肝转移手术切除的病理组织，并进行DKK4染色分析。结果显示：17例结肠癌原发肿瘤中，DKK4染色阳性率35.3% (6/17)，肝转移灶染色阳性率70.6% (7/10)，P = 0.042 (表1)。显微镜下所见，在结肠原发病灶组织中DKK4蛋白主要定位于肿瘤细胞质边缘，胞质和胞核内较少阳性染色。肝转移灶组织中见DKK4蛋白较均匀分布于细胞质内，且染色较深(图2)。该部分结果进一步证实肝转移灶DKK4表达明显高于结肠原发灶。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Differential expression of DKK4 protein in primary and liver metastases of colon cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle"  colspan="2"  >DKK4蛋白表达(例数)</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >阴性</td></tr><tr><td align="center" valign="middle" >结肠原发灶</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >11</td><td align="center" valign="middle"  rowspan="2"  >0.042</td></tr><tr><td align="center" valign="middle" >肝转移灶</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >5</td></tr></tbody></table></table-wrap><p>表1. 结肠癌原发灶与肝转移灶DKK4蛋白的表达差异分析</p><p>图2. 结肠癌原发灶和肝转移灶DKK4蛋白的表达差异</p></sec><sec id="s5_2"><title>3.2. CRISPR/Cas9敲除DKK4基因的效果</title><p>对人结肠癌SW480细胞进行CRISPR/Cas9敲除DKK4基因，转染和药物筛选后48小时见部分细胞呈绿色荧光(GFP阳性)，持续药物筛选后存活细胞均呈绿色荧光表达，生长状态良好，提示载体转染成功(图3)。收集经药物筛选和流式细胞分选的阳性细胞，蛋白电泳结果显示，阳性细胞中DKK4蛋白表达明显下降(图4)。RT-PCR结果亦显示阳性细胞中DKK4表达量接近空白对照水平。验证结果提示CRISPR/Cas9敲除SW480细胞DKK4基因的效果良好。</p><p>图3. 结肠癌原发灶和肝转移灶DKK4蛋白的表达差异</p><p>图4. CRISPR/Cas9敲除人结肠癌细胞DKK4后的蛋白表达情况</p></sec><sec id="s5_3"><title>3.3. 转染细胞5-FU药敏试验</title><p>在正常培养基中，野生型DKK4和DKK4-KO SW480人结肠癌细胞的增殖过程无明显差异(图5(a))。在含有5%、10% 5-FU的培养基中，WT-DKK4 SW480细胞尚可继续保持增殖，但DKK4-KO SW480细胞则随5-FU浓度增加而加速死亡(图5(b))。</p><p>图5. 5-FU作用下野生型和DKK4-KO 人结肠癌SW480细胞的生长情况</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>本研究首先通过临床肿瘤组织标本检测，证实肝转移灶中DKK4蛋白的表达明显高于结肠原发病灶；再通过CRISPR/Cas9技术敲除人结肠癌细胞DKK4基因，并进行5-FU药敏试验，结果显示敲除DKK4表达的结肠癌细胞对5-FU失去耐药性，在5-FU作用下比野生型细胞更容易死亡。该结果与既往研究提示DKK4能诱导肿瘤细胞耐受5-FU的结果相一致。</p><p>人类DKKs家族蛋白共有4种，DKK4是其中一种，也是目前为止了解最少的一个成员。DKK4最早由Krupnik等人在1999年首次报道 [<xref ref-type="bibr" rid="hanspub.28367-ref5">5</xref>] ，目前已知人类DKK4基因定位于常染色体8p11.2~p11.1，蛋白分子量约34kDa [<xref ref-type="bibr" rid="hanspub.28367-ref6">6</xref>] 。在正常成人的组织中DKK4表达量比较低，但在炎症和肿瘤等病理状态下可出现表达异常：如在溃疡型结肠炎、胃癌、食管癌、子宫内膜癌和肾癌组织均可检测到DKK4 mRNA或蛋白的表达升高 [<xref ref-type="bibr" rid="hanspub.28367-ref7">7</xref>] - [<xref ref-type="bibr" rid="hanspub.28367-ref12">12</xref>] ；而在肝细胞癌中DKK4蛋白多呈表达下调，可能与肝癌细胞中DKK4基因常有杂合性丢失有关 [<xref ref-type="bibr" rid="hanspub.28367-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.28367-ref14">14</xref>] 。结直肠癌中DKK4的表达状态目前尚有争议：有研究显示结直肠癌组织中DKK4 mRNA表达明显高于周围正常粘膜，但也有报道认为DKK4在结肠癌细胞中呈表达下调；且在不同人结肠癌细胞系中DKK4表达水平也有差异 [<xref ref-type="bibr" rid="hanspub.28367-ref15">15</xref>] 。而作者既往的研究和本研究结果均证实，肝转移灶中DKK4蛋白和mRNA的表达水平均明显高于结肠原发病灶。这也与临床上常见化疗过程中结直肠癌原发灶比肝转移灶更容易出现退缩的现象相符。文献报道也认为，结直肠癌细胞中DKK4的表达增多可增加细胞自身对5-FU的耐受性：Ebert等对74例接受以5-FU为基础的辅助化疗的结直肠癌患者进行疗效和病理分析，结果也显示化疗的有效性与肿瘤组织中TFAP2E的甲基化状态和DKK4的表达水平密切相关，且不受MSI状态、5-FU代谢途径的影响 [<xref ref-type="bibr" rid="hanspub.28367-ref3">3</xref>] 。</p><p>目前认为DKK4的表达主要受转录因子AP2E (Transcription Factor AP-2E, TFAP2E)的甲基化状态影响：TFAP2E的高度甲基化可激活DKK4启动子，增加DKK4的转录和表达 [<xref ref-type="bibr" rid="hanspub.28367-ref3">3</xref>] ；结直肠癌和胃癌组织标本的检测结果也显示，肿瘤DKK4蛋白表达水平、细胞TFAP2E甲基化程度及肿瘤对5-FU化疗敏感性三者间密切相关，揭示TFAP2E很可能通过DKK4介导作用增强肿瘤细胞对化疗药物的耐药性 [<xref ref-type="bibr" rid="hanspub.28367-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.28367-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.28367-ref18">18</xref>] ，但具体机制仍未明确。而根据DKK4的生物学活性，目前认为DKK4是经典Wnt信号通路的一个拮抗剂，主要抑制上游FZD-Wnt低密度脂蛋白受体相关蛋白5/6 (LRP5/6)复合物的形成，继而阻断Wnt信号的下传，使胞内β-catenin维持磷酸化，最后被蛋白酶体降解而无法在胞核内积聚 [<xref ref-type="bibr" rid="hanspub.28367-ref14">14</xref>] 。在肾癌模型中，当上调肿瘤细胞DKK4的表达后，可观察到一系列Wnt/β-catenin靶基因的表达下降 [<xref ref-type="bibr" rid="hanspub.28367-ref19">19</xref>] 。然而，新近研究发现，某些情况下过表达DKK4对肿瘤有促进作用：如对低表达DKK4的人结肠癌细胞系DLD-1进行过表达修饰，可明显增强肿瘤细胞的体外迁移和侵袭能力，沉默表达DKK4后这些细胞功能则受到抑制 [<xref ref-type="bibr" rid="hanspub.28367-ref20">20</xref>] 。因此，虽然DKK4被认为是Wnt/β-catenin信号通路的一个抑制物，但其对某些肿瘤的促进作用提示DKK4的功能可能不仅仅涉及Wnt/β-catenin。而DKK4如何增强肿瘤对5-FU耐受性的机制仍未清楚。</p><p>总括而言，本研究通过观察性研究证实肝转移灶组织中DKK4的表达明显高于结肠癌原发灶，并利用CRISPR/Cas9技术敲除DKK4基因，发现DKK4对结肠癌细胞耐受5-FU杀伤有极为重要的作用。但本研究仅局限于体外细胞的基因敲除试验，相关分子机制及通路仍有待深入探讨和研究，并需更多动物试验和临床数据进一步验证DKK4在5-FU化疗耐药中的重要性。</p></sec><sec id="s7"><title>5. 结论</title><p>结肠癌肝转移灶组织中有更高水平DKK4表达，且DKK4表达水平对结肠癌细胞耐受5-FU杀伤有极为重要的影响，提示DKK4可能是影响肿瘤耐受5-FU化疗的重要因素和潜在治疗靶点。</p></sec><sec id="s8"><title>文章引用</title><p>黄志良,曾 祥,徐厚巍,王 佳,刘海鹰. DKK4增强结肠癌细胞5-FU耐药的作用和意义Effect of DKK4 Enhancing 5-FU Resistance in Colon Cancer[J]. 世界肿瘤研究, 2019, 09(01): 13-20. https://doi.org/10.12677/WJCR.2019.91003</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28367-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ren, J.S., Masuyer, E., et al. (2013) Estimates of Global Cancer Prevalence for 27 Sites in the Adult Population in 2008. International Journal of Cancer, 132, 1133-1145. https://doi.org/10.1002/ijc.27711</mixed-citation></ref><ref id="hanspub.28367-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rejhová, A., Opattová, A., Čumová, A., et al. (2018) Natural Compounds and Combination Therapy in Colorectal Cancer Treatment. European Journal of Medicinal Chemistry, 144, 582-594.  
https://doi.org/10.1016/j.ejmech.2017.12.039</mixed-citation></ref><ref id="hanspub.28367-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ebert, M.P., Tänzer, M., Balluff, B., et al. (2012) TFAP2E-DKK4 and Chemoresistance in Colorectal Cancer. New England Journal of Medicine, 366, 44-53. https://doi.org/10.1056/NEJMoa1009473</mixed-citation></ref><ref id="hanspub.28367-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chen, H.J., Sun, J., Huang, Z., et al. (2015) Comprehensive Models of Human Primary and Metastatic Colorectal Tumors in Immunodeficient and Immunocompetent Mice by Chemokine Targeting. Nature Biotechnology, 33, 656-660.  
https://doi.org/10.1038/nbt.3239</mixed-citation></ref><ref id="hanspub.28367-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sanjuan, X., Fernandez, P.L., Castells, A., et al. (1997) Differential Expression of Galectin 3 and Galectin 1 in Colorectal Cancer Progression. Gastroenterology, 113, 1906-1915. https://doi.org/10.1016/S0016-5085(97)70010-6</mixed-citation></ref><ref id="hanspub.28367-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Amaravadi L, Brown DE, Guyot D, et al. Functional and struc-tural diversity of the human Dickkopf gene family. Gene 238: 301-313, 1999. https://doi.org/10.1016/S0378-1119(99)00365-0</mixed-citation></ref><ref id="hanspub.28367-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Pineau, P., Nagai, H., Prigent, S., et al. (1999) Identification of Three Distinct Regions of Allelic Deletions on the Short Arm of Chromosome 8 in Hepatocellular Carcinoma. Oncogene, 18, 3127-3134.  
https://doi.org/10.1038/sj.onc.1202648</mixed-citation></ref><ref id="hanspub.28367-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Aung, P.P., Oue, N., Mitani, Y., et al. (2006) Systematic Search for Gastric Cancer Specific Genes Based on SAGE Data: Melanoma Inhibitory Activity and Matrix Metalloproteinase-10 Are Novel Prognostic Factors in Patients with Gastric Cancer. Oncogene, 25, 2546-2557. https://doi.org/10.1038/sj.onc.1209279</mixed-citation></ref><ref id="hanspub.28367-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ali, I., Rafiee, P., Hogan, W.J., et al. (2006) Dickkopf Homologs in Squamous Mucosa of Esophagitis Patients Are Overexpressed Compared with Barrett’s Patients and Healthy Controls. The American Journal of Gastroenterology, 101, 1437-1448. https://doi.org/10.1111/j.1572-0241.2006.00584.x</mixed-citation></ref><ref id="hanspub.28367-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wong, Y.F., Cheung, T.H., Lo, K.W., et al. (2007) Identification of Molecular Markers and Signaling Pathway in Endometrial Cancer in Hong Kong Chinese Women by Genome-Wide Gene Expression Profiling. Oncogene, 26, 1971-1982. https://doi.org/10.1038/sj.onc.1209986</mixed-citation></ref><ref id="hanspub.28367-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">You, J., Nguyen, A.V., Albers, C.G., et al. (2008) Wnt Pathway-Related Gene Expression in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 53, 1013-1019. https://doi.org/10.1007/s10620-007-9973-3</mixed-citation></ref><ref id="hanspub.28367-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Xi, Y., Formentini, A., Nakajima, G., et al. (2008) Validation of Bi-omarkers Associated with 5-Fluorouracil and Thymidylate Synthase in Colorectal Cancer. Oncology Reports, 19, 257-262. https://doi.org/10.3892/or.19.1.257</mixed-citation></ref><ref id="hanspub.28367-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Pendas-Franco, N., Garcia, J.M., Pena, C., et al. (2008) DICKKOPF-4 Is In-duced by TCF/Betacatenin and Upregulated in Human Colon Cancer, Promotes Tumour Cell Invasion and Angiogenesis and Is Repressed by 1α,25-Dihydroxyvitamin D3. Oncogene, 27, 4467-4477. https://doi.org/10.1038/onc.2008.88</mixed-citation></ref><ref id="hanspub.28367-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Fatima, S., Luk, J.M., Poon, R.T., et al. (2014) Dysregulated Expression of Dickkopfs for Potential Detection of Hepatocellular Car-cinoma. Expert Review of Molecular Diagnostics, 14, 535-548.  
https://doi.org/10.1586/14737159.2014.915747</mixed-citation></ref><ref id="hanspub.28367-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Fatima, S., Lee, N.P. and Luk, J.M. (2011) Dickkopfs and Wnt/β-Catenin Signalling in Liver Cancer. World Journal of Clinical Oncology, 2, 311-325. https://doi.org/10.5306/wjco.v2.i8.311</mixed-citation></ref><ref id="hanspub.28367-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Baehs, S., Herbst, A., Thieme, S.E., et al. (2009) Dickkopf-4 Is Frequently Down-Regulated and Inhibits Growth of Colorectal Cancer Cells. Cancer Letters, 276, 152-159. https://doi.org/10.1016/j.canlet.2008.11.003</mixed-citation></ref><ref id="hanspub.28367-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Sun, J., Du, N., Li, J., et al. (2015) Transcription Factor AP2E: A Potential Predictor of Chemoresistance in Patients With Gastric Cancer. Technology in Cancer Research &amp; Treatment, 15, 285-295.  
https://doi.org/10.1177/1533034615577028</mixed-citation></ref><ref id="hanspub.28367-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Park, S.J., Kim, S.M., Hong, Y.S., et al. (2015) TFAP2E Methylation Status and Prognosis of Patients with Radically Resected Colorectal Cancer. Oncology, 88, 122-132. https://doi.org/10.1159/000362820</mixed-citation></ref><ref id="hanspub.28367-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Z.M., Wang, Y., Huang, R., et al. (2014) TFAP2E Hypermethylation Was Associated with Survival Advantage in Patients with Colorectal Cancer. Journal of Cancer Research and Clinical On-cology, 140, 2119-2127.  
https://doi.org/10.1007/s00432-014-1766-4</mixed-citation></ref><ref id="hanspub.28367-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Hirata, H., Hinoda, Y., Majid, S., et al. (2011) DICKKOPF-4 Activates the Noncanonical c-Jun-NH2 Kinase Signaling Pathway While Inhibiting the Wnt-Canonical Pathway in Human Renal Cell Carcinoma. Cancer, 117, 1649-1660.  
https://doi.org/10.1002/cncr.25666</mixed-citation></ref></ref-list></back></article>